Immunotherapy in ovarian cancer

Czech version

Authors: Vít Weinberger; Luboš Minář
Authors‘ workplace: Gynekologicko-porodnická klinika LF MU a FN Brno, přednosta prof. MUDr. P. Ventruba, DrSc.
Published in: Ceska Gynekol 2012; 77(2): 145-152
Category: Original Article

Overview

In the last decade we have witnessed a stormy development in the field of molecular biology, immunology and genetics. Dramatic advances in laboratory and clinical procedures in cellular immunotherapy, along with the development of powerful immunomodulatory agents, created new conditions and opportunities in the treatment of ovarian cancer. The review article provides an overview of the current state of immunotherapy, outlines modern trends in the development of vaccines and immunomodulatory therapies available for immediate clinical testing in cases of advanced ovaria cancer.

Key words:
immunotherapy, vaccines, ovarian cancer.

Sources

1. Aoki, Y., Takakuwa, K., Kodama, S., et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovaria cancer. Cancer Res, 1991, 51, p. 1934–1939.

2. Banchereau, J., Steinman, RM. Dendritic cells and the control of immunity. Nature, 1998, 392, p. 245–252.

3. Bast, RC. Jr, Feeney, M., Lazarus, H., et al. Reaktivity of a monoclonal antibody with human ovarian carcinoma. J Clin Incest, 1981, 68, p. 1331–1337.

4. Bast, RC. Jr, Siegal, FP., Runowicz, C., et al. Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol Oncol, 1985, 22, p. 115–120.

5. Berd, D., Kairys, J., Dunton, C., et al. Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol, 1998, 25, p. 646–653.

6. Brune, IB., Wilke, W., Hensler, T., et al. Downregulation of T helper type 1 immune response and altered pro-inflammatory and antiinflammatory T cell cytokine balance following conventional but not laparoscopic surgery. Am J Surg, 1999, 177, p. 55–60.

7. Brossart, P., Wirths, S., Stuhler, G., et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood, 2000, 96, p. 3102–3108.

8. Bukowski, RM., Ozols, RF., Markman, M. The management of recurrent ovarian cancer. Semin Oncol, 2007, 34, p. S1–15.

9. Coley, WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res, 1991, 3–11.

10. Coliva, A., Zacchetti, A., Luison, E., et al. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol.

11. Curiel, TJ., Coukos, G., Zou, L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 2004, 10, p. 942–949.

12. Dhodapkar, MV., Dhodapkar, KM., Palucka, AK. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell Death Digger, 2008, 15, p. 39–50.

13. Diefenbach, CS., Gnjatic, S., Sabbatini, P., et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res, 2008, 14, p. 2740–2748.

14. Disis, ML., Gooley, TA., Rinn, K., et al. Generation of T-cell immunity to the HER2/neu protein after active immunization with HER2/neu peptide-based vaccines. J Clin Oncol, 2002, 20, p. 2624–2632.

15. Dudley, ME., Wunderlich, JR., Yang, JC., et al. Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 2005, 23, p. 2346–2357.

16. Kenemans, P. CA 125 and OA 3 as target antigens for immunodiagnosis and immunotherapy in ovarian cancer. Eur J Obstet Gynecol Reprod Biol, 1990, 36, p. 221-228.

17. Fujita, K., Ikarashi, H., Takakuwa, K., et al. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res, 1995, 1, p. 501–507.

18. Gong, J., Nikrui, N., Chen, D., et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol, 2000, 165, p. 1705–1711.

19. Goodell, V., Salazar, LG., Urban, N., et al. Antipody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol, 2006, 24, p. 762–768.

20. Hensler, T., Hecker, H., Heeg, K., et al. Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun, 1997, 65, p. 2283–2291.

21. Hird, V., Maraveyas, A., Snook, D., et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer, 1993, 68, p. 403–406.

22. Chu, CS., Kim, SH., June, CH., Coukos, G. Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther, 2008, 8, p. 243–257.

23. Chu, CS., Kim, SH., June, CH., et al. Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther, 2008, 8, p. 243–257.

24. Li, Z. Priming of T cells by heat shock protein-peptide complexes as the basis of tumor vaccines. Semin Immunol, 1997, 9, p. 315–322.

25. Lindquist, S., Craig, EA. The heat-shock proteins. Ann Rev Genet, 1988, 22, p. 631–677.

26. Ludewig, B., Odermatt, B., Landmann, S., et al. Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J Exp Med, 1998, 188, p. 1493–1501.

27. Nagaraj, S., Gabrilovich, DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res, 2008, 68, p. 2561–2563.

28. Nagaraj, S., Gabrilovich, DI. Myeloid-derived suppressor cells. Adv Exp Med Biol, 2007, 601, p. 213–223.

29. Nemunaitis, J., Sterman, D., Jablons, D., et al. Granulocyte-macrophage colonystimulating factor gene-modified autologous tumor vaccines in nonsmall-cell lung cancer. J Natl Cancer Inst, 2004, 96, p. 326–331.

30. Odunsi, K., Jungbluth, AA., Stockert, E., et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res, 2003, 63, p. 6076–6083.

31. Ozols, RF. Systemic therapy for ovarian cancer: Current status and new treatments. Semin Oncol, 2006, 33, p. S3–11.

32. Pfisterer, J., du Bois, A., Sehouli, J., et al. The anti-idiotypic antipody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol, 2006, 17, p. 1568–1577.

33. Reinartz, S., Kohler, S., Schlebusch, H., et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res, 2004, 10, p. 1580–1587.

34. Rosen, DG., Wang, L., Atkinson, JN., et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol, 2005, 99, p. 267–277.

35. Rosenblum, MG., Verschraegen, CF., Murray, JL., et al. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin Cancer Res, 1999, 5, p. 953–961.

36. Sadelain, M., Riviere, I., Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer, 2003, 3, p. 35–45.

37. Sandmaier, BM., Oparin, DV., Holmberg, LA., et al. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother, 1999, 22, p. 54–66.

38. Sato, E., Olson, SH., Ahn, J., et al. Intraepithelial CD8+ tumorinfiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA, 2005, 102, p. 18538–18543.

39. Schlienger, K., Chu, CS., Woo, EY., et al. TRANCE – and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res, 2003, 9, p. 1517–1527.

40. Schmeler, KM., Vadhan-Raj, S., Ramirez, PT., et al. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol, 2009, 113, p. 210–215.

41. Sica, A., Bronte, V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest, 2007, 117, p. 1155–1166.

42. Srivastava, P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Ann Rev Immunol 2002, 20, p. 395–425.

43. Steinman, RM. The dendritic cell system and its role in immunogenicity. Ann Rev Immunol, 1991, 9, p. 271–296.

44. Steinman, RM., Banchereau, J. Taking dendritic cells into medicine. Nature, 2007, 449, p. 419–426.

45. Špíšek, R., Horváth, R., Kayserová, J., Bartůňková, J. Možnosti protinádorové terapie u karcinomu prostaty, Lék Listy, 2010, 6, p. 9–13.

46. Tomšova, M., Melichar, B., Sedlakova, I., Steiner, I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol, 2008, 108, p. 415–420.

47. Vlad, AM., Kettel, JC., Alajez, NM., et al. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004, 82, p. 249–293.

48. Wolf, D., Wolf, AM., Rumpold, H., Fiegl, H., et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res, 2005, 11, p. 8326–8331.

49. Zhang, L., Conejo-Garcia, JR., Katsaros, D., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med, 2003, 348, p. 203–213.